A 63bp Deletion in the Promoter of RAGE Correlates with a Decreased Risk for Nephropathy in Patients with Type 2 Diabetes

Experimental and Clinical Endocrinology and Diabetes

Volumn 112, Issue 3, 2004, Pages 135-141

  Rudofsky Jr , G ^a   Isermann, B ^a   Schilling, T ^a   Schiekofer, S ^a   Andrassy, M ^a   Schneider, J G ^a   Morcos, M ^a   Humpert, P M ^a   Sayed, A A R ^a   Witte, S ^a   Renn, W ^b   Pfohl, M ^c   Hamann, A ^a   Nosikov, V ^d   Schleicher, E ^b   Haring H U ^b   Rudofsky Sen , G ^e   Ritz, E ^a   Nawroth, P P ^a   Bierhaus, Angelika ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c Medizinische Klinik I   (Germany)

^d STATE RESEARCH INSTITUTE OF GENETICS AND SELECTION OF INDUSTRIAL MICROORGANISMS   (Russian Federation)

^e UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Diabetes mellitus; Diabetic nephropathy; Polymorphism; Receptor of advanced glycation endproducts

Indexed keywords

ADVANCED GLYCATION END PRODUCT;

ADULT; ARTICLE; DIABETIC NEPHROPATHY; FEMALE; GENE; GENE DELETION; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY; HUMAN; HUMAN CELL; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOPOROSIS; OUTCOMES RESEARCH; PATHOPHYSIOLOGY; PILOT STUDY; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; PROMOTER REGION; RAGE GENE;

ANTIGENS, NEOPLASM; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; GENOTYPE; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PREVALENCE; PROMOTER REGIONS (GENETICS); REFERENCE VALUES; RISK; SEQUENCE DELETION;

EID: 11144354724     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-817822     Document Type: Article

References (56)

1. Abel M, Ritthaler U, Zhang Y, Deng Y, Schmidt AM, Greten J, Sernau T, Wahl P, Andrassy K, Ritz E, Waldherr R, Stern DM, Nawroth PP. Expression of receptors for advanced glycosylated end products in renal disease. Nephrol Dial Transplant 1995; 10: 1662-1667
2. Aiello LP, Wong JS. Role of vascular endothelial growth factor in diabetic vascular complications. Kidney Int 2000; 58 (Suppl 77): S113-119
3. Beisswenger PJ, Makita Z, Curphey TJ, Moore LL, Jean S, Brinck-Johnsen T, Bucala R, Vlassara H. Formation of immunochemical advanced glycosylation end products preceedes and correlates with early manifestions of renal and retinal disease in diabetes. Diabetes 1995; 44: 824-829
4. Bierhaus A, Kasper M, Arnold B, Nawroth PP. Deletion von RAGE bedingt in RAGE -/- Mäusen einen proinflammatorischen Phänotyp. Diabet Stoffw 2003; 12: 80
5. Bierhaus A, Ritz E, Nawroth PP. Expression of receptors for advanced glycation end-products in occlusive vascular and renal disease. Nephrol Dial Transplant 1996; 11 (Suppl 5): 87-90
6. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988; 318: 1315-1321
7. Festa A, D'Agostino R, Howard G, Mykkanen L, Tracy RP, Haffner SM. Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: The Insulin Resistance Atherosclerosis Study. Kidney Int 2000; 58: 1703-1710
8. Fogarty DG, Hanna LS, Wantman M, Warram JH, Krolewski AS, Rich SS. Segregation analysis of urinary albumin excretion in families with type 2 diabetes. Diabetes 2000; 49: 1057-1063
9. Hofmann MA, Drury S, Fu C, Wu Q, Taguchi A, Lu Y, Avila C, Kambham N, Slattery T, Beach D, McClary J, Nagashima M, Morser J, Bierhaus A, Neurath M, Nawroth P, Stern D, Schmidt AM. RAGE mediates a novel proinflammatory axis. The cell surface receptor for S100/calgranulin polypeptides. Cell 1999; 97: 889-901
10. Hofmann MA, Drury S, Hudson BI, Gleason MR, Qu W, Lu Y, Lalla E, Chitnis S, Monteiro J, Stickland MH, Bucciarelli LG, Moser B, Moxley G, Itescu S, Grant PJ, Gregersen PK, Stern DM, Schmidt AM. RAGE and arthritis: the G82S polymorphism amplifies the inflammatory response. Genes Immun 2002; 3: 123-135
11. Holla LI, Kahkova K, Fassmann A, Buckova D, Halabala T, Znojil V, Vanek J. Diatribution of the receptor for advanced glycation end products gene polymorphisms in patients with chronic periodontitis: a preliminary study. J Peridontol 2001; 72: 1742-1746
12. Horie K, Miyata T, Maeda K, Miyata S, Sugiyama S, Sakai H, van Ypersele de Strihou C, Monnier VM, Witztum JL, Kurokawa K. Immunhistochemical colocalization of glycoxidant products and lipid peroxidation products in diabetic renal glomerular lesions: implication for glycooxidative stress in the pathogenesis of diabetic nephropathy. J Clin Invest 1997; 100: 2995-3004
13. Hudson BI, Stickland MH, Futers TS, Grant PJ. Effects of novel polymorphisms in the RAGE gene on transcriptional regulation and their association with diabetic retinopathy. Diabetes 2001; 50: 1505-1511
14. Hudson BI, Stickland MH, Grant PJ. Identification of polymorphisms in the receptor for advanced glycation end products (RAGE) gene: prevalence in type 2 diabetes and ethnic groups. Diabetes 1998; 47: 1155-1157
15. Isermann B, Schmidt S, Bierhaus A, Schiekofer S, Borcea V, Ziegler R, Nawroth PP, Ritz E. (CA)(n) dinucleotide repeat polymorphism at the 5′-end of the aldose reductase gene is not associated with microangiopathy in Caucasians with long-term diabetes mellitus 1. Nephrol Dial Transplant 2000; 15: 918-920
16. Kankova K, Beranek M, Hajek D, Vlkova E. Polymorphisms 1704 G/T, 2184 A/G, and 2245 G/A in the RAGE gene are not associated with diabetic retinopathy in NIDDM: pilot study. Retina 2002; 22: 119-121
17. Kankova K, Marova I, Zahejsky J, Muzik J, Stejskalova A, Znojil V, Vacha J. Polymorphisms 1704 G/T and 2184 A/G in the RAGE gene are associated with antioxidant status. Metabolism 2001a; 50: 1152-1160
18. Kankova K, Vasku A, Hajek D, Zahejsky J, Vasku V. Association of G82S polymorphism in the RAGE gene with skin complications in type 2 diabetes. Diabetes Care 1999; 22: 1745
19. Kankova K, Zahejsky JV, Marova I I, Muzik J, Kuhrova V V, Blazkova M, Znojil V, Beranek M, Vacha JV. Polymorphisms in the RAGE gene influence susceptibility to diabetes-associated microvascular dermatoses in NIDDM. J Diabetes Complications 2001b; 15: 185-192
20. Kislinger T, Fu C, Huber B, Qu W, Taguchi A, Du Yan S, Hofmann M, Yan SF, Pischetsrieder M, Stern D, Schmidt AM. N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem 1999; 274: 31740-31749
21. Landin-Olsson M. Latent autoimmune diabetes in adults. Ann NY Acad Sci 2002; 958: 112-116
22. Lawrence T, Gilroy DW, Colville-Nash PR, Willoughby DA. Possible new role for NF-kappaB in the resolution of inflammation. Nat Med 2001; 7: 1291-1297
23. Liu L, Xiang K. RAGE Gly82Ser polymorphism in diabetic microangiopathy. Diabetes Care 1999; 22: 646
24. Makita Z, Bucala R, Rayfield EA, Yang Z, Skolnik E, Friedman EA, Cerami A, Vlassara H. Advanced glycosylation endproducts in patients with diabetic nephropathy. N Engl J Med 1991; 325: 836-842
25. Makita Z, Yanagisawa K, Kuwajima S, Yoshioka N, Atsumi T, Hasunuma Y, Koike T. Advanced glycation endproducts and diabetic nephropathy. J Diabetes Complications 1995; 9: 265-268
26. McCance DR, Dyer DG, Dunn JA, Bailic KE, Thorpe SR, Baynes JW, Lyons TJ. Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus. J Clin Invest 1993; 91: 2470-2478
27. Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, Pan YC, Elliston K, Stern D, Shaw A. Cloning and expression of a cell surface receptor for advanced glycosylation endproducts of proteins. J Biol Chem 1992; 267: 14998-15004
28. Nishino T, Horii Y, Shiiki H, Yamamoto H, Makita Z, Bucala R, Dohi K. Immunohistochemical detection of advanced glycosylation end products within the vascular lesions and glomeruli in diabetic nephropathy. Hum Pathol 1995; 26: 308-313
29. O'Rahilly S, Wainscoat JS, Turner RC. Type 2 (insulin-dependent) diabetes mellitus. New genetics for old night mares. Diabetologia 1988; 31: 407-414
30. Orita M, Iwahana H, Kanagawa H, Hayashi K, Sekiya T. Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. Proc Natl Acad Sci USA 1989; 86: 2766-2770
31. Park L, Raman KG, Lee KJ, Lu Y, Ferran LJ, Chow WS, Stern D, Schmidt AM. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 1998; 4: 1025-1031
32. Pettersson-Fernholm K, Forsblom C, Hudson BI, Perola M, Grant PJ, Groop P. The functional - 374 T/A RAGE gene polymorphism is associated with proteinuria and cardiovascular disease in type 1 diabetic patients. Diabetes 2003; 52: 891-894
33. Pickup JC, Crook MA. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 1998; 41: 1241-1248
34. Poirier O, Nicaud V, Vionnet N, Raoux S, Tarnow L, Vlassara H, Parving HH, Cambien F. Polymorphism screening of four genes encoding advanced glycation endproduct putative receptors. Association study with nephropathy in type 1 diabetic patients. Diabetes 2001; 50: 1214-1218
35. Prevost G, Fajardy I, Fontaine P, Danze PM, Besmond C. Human RAGE GLY82SER dimorphism and HLA class II DRB1-DQA1-DQB1 haplotypes in type 1 diabetes. Eur J Immunogenet 1999; 26: 343-348
36. Schenk S, Schraml P, Bendik I, Ludwig CU. A novel polymorphism in the promotor of the RAGE gene is associated with non-small cell lung cancer. Lung cancer 2001; 32: 7-12
37. Schmidt AM, Hofmann M, Taguchi A, Yan SD, Stern DM. RAGE: a multiligand receptor contributing to the cellular response in diabetic vasculopathy and inflammation. Sem Thromb Hemost 2000a; 26: 485-494
38. Schmidt AM, Hori O, Brett J, Yan SD, Wautier JL, Stern D. Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arterioscler Thromb 1994; 14: 1521-1528
39. Schmidt AM, Yan SD, Wautier JL, Stern D. Activation of receptor for advanced glycation end products. A mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 1999; 84: 489-497
40. Schmidt AM, Yan SD, Stern DM. The dark side of glucose. Nature Med 1995; 1: 1002-1004
41. Schmidt AM, Yan SD, Yan SF, Stern DM. The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta 2000b; 1498: 99-111
42. Seaquist ER, Goetz FC, Rich S, Barbosa J. Familial clustering of diabetic kidney disease: evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med 1989; 320: 1161-1165
43. Stern DM, Yan SD, Yan SF, Schmidt AM. Receptor for advanced glycation endproducts (RAGE) and the complications of diabetes. Aging Res Rev 2002; 1: 1-15
44. Tanji N, Markowitz GS, Fu C, Kislinger T, Taguchi A, Pischetsrieder M, Stern D, Schmidt AM, D'Agati VD. Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J Am Soc Nephrol 2000; 11: 1656-1666
45. Thomsen G, Robinsin WP, Kuhner MK, Joe S, MacDonald MJ, Gottschall JL, Barbosa J, Rich SS, Bertrams J, Baur MP. Genetic heterogeneity, modes of inheritance and risk estimates for a join study of Caucasians with insulin-dependent diabetes mellitus. Am J Hum Genet 1988; 43: 799-816
46. Thornalley PJ. Cell activation by glycated proteins. AGE receptors, receptor recognition factors and functional classification of AGEs. Cell Mol Biol 1998; 44: 1013-1023
47. Vasku VV, Kankova K, Vasku A, Muzik J, Izakovicova Holla L, Semradova VV, Vacha J. Gene polymorphisms (G82 S, 1704 G/T, 2184 A/G and 2245 G/A) of the receptor of advanced glycation end products (RAGE) in plaque psoriasis. Arch Dermatol Res 2002; 294: 127-130
48. Vlassara H. Advanced glycation in diabetic renal and vascular disease. Kidney Int 1995; 48 (Suppl 51): 43-44
49. Vlassara H, Striker LJ, Teichberg S, Fuh H, Li YM, Steffes M. Advanced glycosylation endproducts induce glomerular sclerosis and albuminuria in normal rats. Proc Nat Acad Sci 1994; 91: 11704-11708
50. Wautier JL, Guillausseau PJ. Advanced glycation end products, their receptors and diabetic angiopathy. Diabetes Metab 2001; 27: 535-542
51. Wautier JL, Guillausseau PJ. Diabetes, advanced glycation endproducts and vascular disease. Vascular Medicine 1998; 3: 131-137
52. Wautier JL, Zoukourian C, Chappey O, Wautier MP, Guillausseau PJ, Cao R, Hori O, Stern D, Schmidt AM. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy: soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J Clin Invest 1996; 97: 238-243
53. Wendt TM, Tanji N, Guo J, Kislinger TR, Qu W, Lu Y, Bucciarelli LG, Rong LL, Moser B, Markowitz GS, Stein G, Bierhaus A, Lieliensiek B, Arnold B, Nawroth PP, D'Agati VD, Stern DM, Schmidt AM. RAGE drives the development of glomerulosclerosis and implicates early podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 2003; 162: 1123-1137
54. Yamamoto Y, Kato I, Doi T, Yonekura H, Ohashi S, Takeuchi M, Watanabe T, Yamagishi S, Sakurai S, Takasawa S, Okamoto H, Yamamoto H. Development and prevention of advanced diabetic nephropathy in RAGE overexpressing mice. J Clin Invest 2001; 108: 261-268
55. Yan SD, Chen X, Fu J, Chen M, Zhu H, Roher A, Slattery T, Zhao L, Nagahima M, Morser J, Migheli A, Nawroth PP, Stern D, Schmidt AM. RAGE and amyloid-β-peptide neurotoxicity in Alzheimer's disease. Nature 1996; 382: 685-691
56. Zimmet P, Turner R, McCarty D, Rowley M, Mackay I. Crucial points at diagnosis. Type 2 diabetes or slow type 1 diabetes. Diabetes care 1999; 22 (Suppl 2): B59-64